GROUP PUBLICATIONS
Ercolano et al, 2020
Racle et al, 2019
Vanoni et al, 2021
Rockinger et al, 2020
Ercolano et al, 2021
Cachot et al, 2021
2021
Scientific Articles
-
Falquet M., Ercolano G., Jandus P., Jandus C. and Trabanelli S. Healthy and patient type 2 innate lymphoid cells are differently affected by in vitro culture conditions. J Asthma and Allergy, 2021:14 773-783.
-
Serino S., Trabanelli S., Jandus C., Fellrath J., Grivaz P., Paladino MP. and Serino A. COVID-19 pandemics sharpens the differentiation of the peripersonal space between self and others. Current Biology 2021, in press
-
Benkhoucha M., Ngoc LT., Breville G., Senoner I., Jandus C. and Lalive P. c-Met enforces proinflammatory and migratory features of human activated CD4+ T cells. Cell Mol Immunol 2021 Jun, https://doi.org/10.1038/s41423-021-00721-9.
-
Ercolano G., Gomez-Cadena A., Dumauthioz N., Vanoni G., Kreutzfeldt M., Wyss T., Michalik L., Loyon R., Ianaro A., Ho P-C., Borg C., Kopf M., Merkler D., Krebs P., Romero P., Trabanelli S. and Jandus C. PPARg drives IL-33 dependent ILC2 pro-tumoral functions. Nat Comm 2021 May; 12(1):2538.
-
Saillard M., Cenerenti M., Romoro P. and Jandus C., Impact of Immunotherapy on CD4 T cell phenotypes and function in Cancer. Vaccines 2021 May; 9(5):454
-
Hofmann M., Jandus C., Lee LN. and Utzschneider DT. Editorial: Memory T cells in chronic infections and tumors. Front Immunol 2021. 12:656010.
-
Cachot A, Bilous M, Liu Y-C, Li X, Saillard M, Cenerenti M, Rockinger AG, Wyss T, et al. Tumor-specific cytolytic CD4 T cells mediate immunity against human cancer. Sci Adv 2021 Feb; 7(9):eabe3348
-
Vanoni G, Ercolano G, Candiani S, Rutigliani M, Lanata M, Derré L, Marcenaro E, Schneider P, et al. Human primed ILCPs support endothelial activation through NF-kB signaling. Elife 2021 Feb, 10:e58838
-
Gomez-Cadena A., Spehner L., Kroemer M., Ben Khelil M., Bouiller K., Verdeil G., Trabanelli S., Borg C., Loyon R. and Jandus C. Severe COVID-19 patients display an ILC2 NKG2D+ population in their impaired ILC compartment. Cell Mol Immunol 2021;18(2):484-486.
2020
Scientific Articles
-
Pesce S, Trabanelli S, Di Vito C, Greppi M, Obino V, Guolo F, Minetto P, Bozzo M, et al. Cancer immunotherapy by blocking immune checkpoints on innate lymphocytes. Cancers 2020;12(12):E3504.
-
Yu YR, Imrichova H, Wang H, Chao T, Xiao Z, Gao M, Rincon-Restrepo M, Franco F, et al. Disturbed mitochondrial dynamics in CD8+ TILs reinforce T cell exhaustion. Nature Immunology 2020 doi:10.1038/s41590-020-0793-3.
-
Gomez-Cadena A, Barreto A, Fiorentino S, Jandus C. Immune system activation by natural products and complex fractions: a network pharmacology approach in cancer treatment. Cell Stress 2020;4(7):154-166.
-
Wang H, Franco F, Tsui Y-C, Xie X, Trefny MP, Zappasodi R, Mohmood SR, Fernández-García J, et al. CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors. Nature Immunology 2020;21(3):298-308.
-
Ercolano G, Wyss T, Salomé B, Romero P, Trabanelli S, Jandus C. Distinct and shared gene expression for human innate versus adaptive helper lymphoid cells. Journal of Leukocyte Biology 2020;108(2):723.737.
-
Ercolano G, Garcia-Garijo A, Salomé B, Gomez Cadena A, Vanoni G, Mastelic-Gavillet B, Ianaro A, Speiser DE, et al. Immunosuppressive mediators impair proinflammatory innate lymphoid cell function in human malignant melanoma. Cancer Immunology Research 2020
-
Lande R, Palazzo R, Gestermann N, Jandus C, Falchi M, Spadaro F, Riccieri V, James EA, et al. Native/citrullinated LL37-specific T-cells help autoantibody production in systemic lupus erythematosus. Scientific Reports 2020;10(1):5851.
-
Rockinger GA, Guillaume P, Cachot A, Saillard M, Speiser DE, Coukos G, Harari A, Romero PJ, et al. Optimized combinatorial pMHC class II multimer labeling for precision immune monitoring of tumor-specific CD4 T cells in patients. Journal for immunotherapy of cancer 2020;8(1):e000435.
Book Chapters
-
Gomez-Cadena A, Romero P, Trabanelli S, Jandus C. Detecting and analyzing murine innate lymphoid cells. Dans: Tumor Immunology and Immunotherapy: Cellular Methods Part A. Cambridge MA: Elsevier; 2020 p. 329-342.
2019
Scientific Articles
-
Mastelic-Gavillet B, Navarro Rodrigo B, Décombaz L, Wang H, Ercolano G, Ahmed R, Lozano LE, Ianaro A, et al. Adenosine mediates functional and metabolic suppression of peripheral and tumor-infiltrating CD8+ T cells. Journal for Immunotherapy of Cancer 2019;7(1):257.
-
Salomé B, Gomez Cadena A, Loyon R, Suffiotti M, Salvestrini V, Wyss T, Vanoni G, Ruan DF, et al. CD56 as a marker of an ILC1-like population with NK cell properties that is functionally impaired in AML. Blood Advances 2019;3(22):3674-3687.
-
Costa-Nunes C, Cachot A, Bobisse S, Arnaud M, Genolet R, Baumgaertner P, Speiser DE, Sousa Alves PM, et al. High-throughput screening of human tumor antigen-specific CD4 T cells, including neoantigen-reactive T cells. Clinical Cancer Research 2019;25(14):4320-4331.
-
Ercolano G, Falquet M, Vanoni G, Trabanelli S, Jandus C. ILC2s: new actors in tumor immunity. Frontiers in Immunology 2019;10:2801.
-
Trabanelli S, Gomez Cadena A, Jandus C. Immunophenotyping of human innate lymphoid cells. Methods in Molecular Biology 2019;2032:179-192.
-
Guay C, Kruit JK, Rome S, Menoud V, Mulder NL, Jurdzinski A, Mancarella F, Sebastiani G, et al. Lymphocyte-derived exosomal microRNAs promote pancreatic β cell death and may contribute to type 1 diabetes development. Cell Metabolism 2019;29(2):348-361.e6.
-
Martinez-Usatorre A, Sempere LF, Carmona SJ, Carretero-Iglesia L, Monnot G, Speiser DE, Rufer N, Donda A, et al. MicroRNA-155 expression is enhanced by T-cell receptor stimulation strength and correlates with improved tumor control in melanoma. Cancer Immunology Research 2019;7(6):1013-1024.
-
Loyon R, Jary M, Salomé B, Gomez Cadena A, Galaine J, Kroemer M, Romero P, Trabanelli S, et al. Peripheral innate lymphoid cells are increased in first line metastatic colorectal carcinoma patients: a negative correlation with th1 immune responses. Frontiers in Immunology 2019;10:2121.
-
Racle J, Michaux J, Rockinger GA, Arnaud M, Bobisse S, Chong C, Guillaume P, Coukos G, et al. Robust prediction of HLA class II epitopes by deep motif deconvolution of immunopeptidomes. Nature Biotechnology 2019;37(11):1283-1286.
-
Haas Q, Boligan KF, Jandus C, Schneider C, Simillion C, Stanczak MA, Haubitz M, Seyed Jafari SM, et al. Siglec-9 regulates an effector memory CD8+ T-cell subset that congregates in the melanoma tumor microenvironment. Cancer Immunology Research 2019;7(5):707-718.
-
Jandus P, Boligan KF, Smith DF, de Graauw E, Grimbacher B, Jandus C, Abdelhafez MM, Despont A, et al. The architecture of the IgG anti-carbohydrate repertoire in primary antibody deficiencies. Blood 2019;134(22):1941-1950.
-
Trabanelli S, Chevalier MF, Derré L, Jandus C. The pro- and anti-tumor role of ILC2s. Seminars in Immunology 2019;41:101276.
-
Jandus C. To be a tumor promoting or tumor suppressing ILC: that is the question. Seminars in Immunology 2019;41:101283.
2018
Scientific Articles
-
Kowalczyk-Quintas C, Chevalley D, Willen L, Jandus C, Vigolo M, Schneider P. Inhibition of membrane-bound BAFF by the anti-BAFF antibody belimumab. Frontiers in Immunology 2018;9:2698.
-
Salomé B, Jandus C. Innate lymphoid cells in antitumor immunity. Journal of Leukocyte Biology 2018;103(3):479-483.
Professional Articles
-
Gourdin N, Bossennec M, Rodriguez C, Vigano S, Machon C, Jandus C, Bauché D, Faget J, et al. Autocrine adenosine regulates tumor polyfunctional CD73+CD4+ effector T cells devoid of immune checkpoints. Cancer Research 2018;78(13):3604-3618.
-
Trabanelli S, Gomez-Cadena A, Salomé B, Michaud K, Mavilio D, Landis BN, Jandus P, Jandus C. Human innate lymphoid cells (ILCs): Toward a uniform immune-phenotyping. Cytometry. Part B, Clinical cytometry 2018;94(3):392-399.
-
Pich C, Meylan P, Mastelic-Gavillet B, Nguyen TN, Loyon R, Trang BK, Moser H, Moret C, et al. Induction of paracrine signaling in metastatic melanoma cells by PPARγ agonist rosiglitazone activates stromal cells and enhances tumor growth. Cancer Research 2018;78(22):6447-6461.
2017
Scientific Articles
-
Lecciso M, Ocadlikova D, Sangaletti S, Trabanelli S, De Marchi E, Orioli E, Pegoraro A, Portararo P, et al. ATP release from chemotherapy-treated dying leukemia cells elicits an immune suppressive effect by increasing regulatory T cells and tolerogenic dendritic cells. Frontiers in Immunology 2017;8:1918.
-
Vigano S, Trabanelli S, Indulsi F, Salomé B, Harari A, Romero P, Helbling A, Jandus C, et al. Dysregulated Innate Lymphocytes in Patients With Primary Antibody Deficiency Treated With Intravenous Immunoglobulin. Journal of Investigational Allergology and Clinical Immunology 2017;27(6):394-396.
-
Suffiotti M, Carmona SJ, Jandus C, Gfeller D. Identification of innate lymphoid cells in single-cell RNA-Seq data. Immunogenetics 2017;69(7):439-450.
-
Chevalier MF, Trabanelli S, Racle J, Salomé B, Cesson V, Gharbi D, Bohner P, Domingos-Pereira S, et al. ILC2-modulated T cell-to-MDSC balance is associated with bladder cancer recurrence. Journal of Clinical Investigation 2017;127(8):2916-2929.
-
Romano M, Sollazzo D, Trabanelli S, Barone M, Polverelli N, Perricone M, Forte D, Luatti S, et al. Mutations in JAK2 and Calreticulin genes are associated with specific alterations of the immune system in myelofibrosis. OncoImmunology 2017;6(10):e1345402.
-
Jandus C, Usatorre AM, Viganò S, Zhang L, Romero P. The vast universe of T cell diversity: subsets of memory cells and their differentiation. Methods in Molecular Biology 2017;1514:1-17.
-
Trabanelli S, Chevalier MF, Martinez-Usatorre A, Gomez Cadena A, Salomé B, Lecciso M, Salvestrini V, Verdeil G, et al. Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis. Nature Communications 2017;8(1):593.
2016
Scientific Articles
-
Scholz G, Jandus C, Zhang L, Grandclément C, Lopez-Mejia IC, Soneson C, Delorenzi M, Fajas L, et al. Modulation of mTOR signalling triggers the formation of stem cell-like memory T cells. EBioMedicine 2016;4:50-61.
-
Ludigs K, Jandus C, Utzschneider DT, Staehli F, Bessoles S, Dang AT, Rota G, Castro W, et al. NLRC5 shields T lymphocytes from NK-cell-mediated elimination under inflammatory conditions. Nature Communications 2016;7:10554.
-
Baumgaertner P, Costa Nunes C, Cachot A, Maby-El Hajjami H, Cagnon L, Braun M, Derré L, Rivals J-P, et al. Vaccination of stage III/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8+ and CD4+ T-cell responses with multiple specificities including a novel DR7-restricted epitope. OncoImmunology 2016;5(10):e1216290.